Indeed, extrapolation to unselected NSCLC patients would give between 0.5% to 1% ROS1-positive cases i.e. similar levels than those reported by Warth et al. (0.6%, 9/1478) and Jurmeister et al. (0,8%, 4/473) [18, 19]. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.